# EDGAR Filing Document

**Accession Number:** 0001802665
**File Stem:** 0001104659-25-092776
**Filing Date:** 2025-9
**Character Count:** 14261
**Document Hash:** 69251aded957f96b8131018ba0dfedbb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-092776.hdr.sgml**: 20250924

**ACCESSION NUMBER**: 0001104659-25-092776

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250924

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250924

**DATE AS OF CHANGE**: 20250924

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Harmony Biosciences Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001802665
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822279923
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39450
- **FILM NUMBER:** 251335400

**BUSINESS ADDRESS:**
- **STREET 1:** 630 W GERMANTOWN PIKE
- **STREET 2:** SUITE 215
- **CITY:** PLYMOUTH MEETING
- **STATE:** PA
- **ZIP:** 19462
- **BUSINESS PHONE:** (484) 539-9800

**MAIL ADDRESS:**
- **STREET 1:** 630 W GERMANTOWN PIKE
- **STREET 2:** SUITE 215
- **CITY:** PLYMOUTH MEETING
- **STATE:** PA
- **ZIP:** 19462

?xml version='1.0' encoding='ASCII'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): September 24, 2025**

## HARMONY BIOSCIENCES HOLDINGS, INC .
**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | **001-39450** | **82-2279923** |
| &nbsp;&nbsp;**(State or other jurisdiction** | **(Commission** | **(IRS Employer** |
| &nbsp;&nbsp;**of incorporation)** | **File Number)** | **Identification No.)** |

---

**630 W. Germantown Pike, Suite 215**

**Plymouth Meeting, PA 19462**

**(Address of principal executive offices) (Zip Code)**

**(484) 539-9800**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| <br>&nbsp;&nbsp;**Title of each class** | &nbsp;&nbsp;**Trading**<br>&nbsp;&nbsp;**Symbol(s)** | &nbsp;&nbsp;**Name of each exchange**<br>&nbsp;&nbsp;**on which registered** |
| &nbsp;&nbsp;**Common Stock, $0.00001 par value per share** | &nbsp;&nbsp;**HRMY** | &nbsp;&nbsp;**The Nasdaq Global Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01. Regulation FD Disclosure.**

On September 24, 2025, Harmony Biosciences Holdings, Inc. (the "Company") issued a press release announcing topline data from its phase 3 registrational trial, the RECONNECT study, which did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate.

The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

**Note Regarding Forward-Looking Statements**

Certain statements in this Current Report on Form 8-K constitute "forward-looking statements" within the meaning of the federal securities laws. These statements are based on management's current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward-looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein including the risks discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission ("SEC,") on February 25, 2025, as well as other factors described from time to time in the Company's filings with the SEC. Such forward-looking statements are made only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update or revise any forward-looking statement because of new information, future events or otherwise, except as otherwise required by law. If it does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit |  |
| &nbsp;&nbsp;No. | Description |
| 99.1\* | [Press release issued by the Company, dated September 24, 2025.](hrmy-20250924xex99d1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

\* This Exhibit is furnished herewith and will not be deemed "filed" for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except to the extent that Harmony Biosciences Holdings, Inc. specifically incorporates it by reference.

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **HARMONY BIOSCIENCES HOLDINGS, INC.** | **HARMONY BIOSCIENCES HOLDINGS, INC.** |
| Date: September 24, 2025 | By: | /s/ Christian Ulrich |
|  |  | Christian Ulrich |
|  |  | SVP and General Counsel |

---

## Exhibit 99.1

Exhibit 99.1

![Graphic](hrmy-20250924xex99d1001.jpg)<br>**HARMONY BIOSCIENCES PROVIDES UPDATE FROM ITS PHASE 3 RECONNECT STUDY OF ZYN002 IN FRAGILE X SYNDROME**

**PLYMOUTH MEETING, Pa., September 24, 2025** -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The RECONNECT Study did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate.

Kumar Budur, M.D., M.S., Chief Medical and Scientific Officer at Harmony Biosciences said, "Although the study did not achieve its primary endpoint, the findings from this study provide valuable insights into Fragile X syndrome, a rare neurobehavioral condition with significant unmet medical need and no FDA-approved therapies. We will conduct a comprehensive analysis of the full dataset to better understand the results as part of our continued commitment to the Fragile X community." Dr. Budur added, "We are grateful to the patients, families, caregivers, clinicians, and researchers who made this trial possible."

The RECONNECT Study was a Phase 3 randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of ZYN002, a pharmaceutically manufactured cannabidiol administered as a transdermal gel to patients with FXS ages 3 to under 30 years old.

"While these results are not what we anticipated, we remain confident in our ability to bring innovative therapies to patients while creating long-term value for shareholders," said Jeffrey M. Dayno, M.D., President and CEO of Harmony Biosciences. "We have a late-stage, catalyst-rich pipeline with multiple Phase 3 programs in the clinic and continue to be on track to initiate our Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year. Harmony's unique profile as a profitable self-funding biotech company with strong cash-generation positions us well to drive future growth."

**About the RECONNECT Study**

The RECONNECT Study was a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of ZYN002. A total of 215 male and female patients, ages 3 to < 30 years, were randomized 1:1 to receive study drug or placebo during an 18-week treatment period. Doses of treatments

------

were weight-based. The primary endpoint for the RECONNECT Study was change from baseline to week 18 in the ABC-C<sub>FXS</sub> Social Avoidance subscale score in patients with complete methylation (≥90%) in the *FMR1* gene. Key secondary endpoints included change from baseline to week 18 in the ABC-C<sub>FXS</sub> Irritability subscale score in patients with complete methylation (≥90%) in the *FMR1* gene.

**About ZYN002**

ZYN002 is the first-and-only pharmaceutically manufactured synthetic cannabidiol devoid of THC and formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. The product is manufactured through a synthetic process in a cGMP facility and is not extracted from the cannabis plant. ZYN002 does not contain THC, the compound that causes the euphoric effect of cannabis, and has the potential to be a nonscheduled product if approved. Cannabidiol, the active ingredient in ZYN002, has been granted orphan drug designation by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of FXS and for the treatment of 22q. Additionally, ZYN002 has received FDA Fast Track designation for the treatment of behavioral symptoms in patients with FXS.

**About Fragile X Syndrome**

Fragile X syndrome (FXS) is a rare genetic disorder that is the leading known cause of both inherited intellectual disability and autism spectrum disorder. The disorder negatively affects synaptic function, plasticity and neuronal connections, and results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. While the exact prevalence is unknown, upwards of 80,000 patients in the US and 121,000 patients in the European Union and the UK are believed to have FXS, based on FXS prevalence estimates of approximately 1 in 4,000 to 7,000 in males and approximately 1 in 8,000 to 11,000 in females. There is a significant unmet medical need in patients living with FXS as there are currently no FDA-approved treatments for this disorder.

FXS is caused by a mutation in *FMR1*, a gene which modulates a number of systems, including the endocannabinoid system, and most critically, codes for a protein called FMRP. The *FMR1* mutation manifests as multiple repeats of a DNA segment, known as the CGG triplet repeat, resulting in deficiency or lack of FMRP. FMRP helps regulate the production of other proteins and plays a role in the development of synapses, which are critical for relaying nerve impulses, and in regulating synaptic plasticity. In people with full mutation of the *FMR1* gene, the CGG segment is repeated more than 200 times, and in most cases causes the gene to not function. Methylation of the *FMR1* gene also plays a role in determining functionality of the gene. In approximately 70% - 75% of patients with FXS, who have complete methylation of the *FMR1* gene, no FMRP is produced, resulting in dysregulation of the endocannabinoid system and severe neurobehavioral symptoms.

------

**About Harmony Biosciences**<br>Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

**Investor Contact:**<br> Matthew Beck

astr partners

917-415-1750

<u>matthew.beck@astrpartners.com</u> 

**Media Contact:**<br>Cate McCanless

Harmony Biosciences<br>202-641-6086<br>cmccanless@harmonybiosciences.com

------